Diabetes and endocrinology specialists at Riley Children’s Health deliver expert care for infants, children and adolescents with diabetes and other endocrine disorders. Our board certified physicians have completed additional subspecialty training in pediatric endocrinology and pediatric diabetology. Ten certified diabetes and education specialists provide a wide range of resources and support to patients and their families. DIABETES & ENDOCRINOLOGY
RESEARCH HIGHLIGHTS
Professional organization affiliations VICE CHAIR Type 1 Diabetes TrialNet Linda A. DiMeglio, MD, MPH SECRETARY Pediatric Endocrine Society Erica A. Eugster, MD CHAIR, PEDIATRIC ENDOCRINOLOGY SUBBOARD American Board of Pediatrics John S. Fuqua, MD CHAIR, TYPE 2 DIABETES WORKING GROUP Type 1 Diabetes Exchange Quality Improvement Collaborative Tamara S. Hannon, MD CO-CHAIR BRAINY-T1D Consortium Linda A. DiMeglio, MD, MPH ASSOCIATE EDITOR Diabetes Care Emily K. Sims, MD
19 active research studies
■ Collaborating with the Herman B Wells Center for Pediatric Research , Riley Children’s is a research study site for novel
endocrine and diabetes therapies to address precocious puberty, Turner syndrome, Noonan syndrome, growth hormone deficiency and Type 2 diabetes. ■ Riley Children’s is one of 18 international centers participating in TrialNet , a major research network focused on Type 1 diabetes prevention and treatment. ■ Our investigators are also involved in studies of the microbiome in Type 1 diabetes, as well as research related to new technologies and therapeutics. We are engaged in clinical trials for therapies designed to modify the course of Type 1 diabetes: ■ TADPOL (Targeting Type 1 Diabetes via Polyamines) Phase II study evaluating the efficacy and safety of difluoromethylornithine ■ JAKPOT T1D NIH-funded Phase II trial evaluating janus kinase inhibitors abrocitinib and ritlecitinib
Premier programs
Novel procedures and advanced technologies
TOP DISTINCTIONS
Riley Children’s is a clinical trial site for therapies designed to modify the course of Type 1 diabetes. This includes a study examining the safety and efficacy of the breakthrough therapy teplizumab in children younger than 8 years old with early-stage disease. In 2023, a patient at Riley Children’s became the first child in Indiana to receive teplizumab .
■ One of the first pediatric programs in the Midwest (and first in Indiana) to administer teplizumab (the first FDA- approved preventive treatment for Type 1 diabetes) ■ Only comprehensive care center in the Midwest for congenital adrenal hyperplasia; one of eight Comprehensive Care Centers
■ Early-Stage Type 1 Diabetes Program ■ Endocrine Diseases Newborn Screening Program (statewide) ■ Youth Diabetes Prevention Program (for children at risk for diabetes) ■ Multidisciplinary programs – Differences of Sex Development Program – Gender Health Program – Late Endocrine Effects of Cancer Therapy Program – Metabolic Bone Disease Program – Muscular Dystrophy Program ■ Young Adult Diabetes Transition Program
of Excellence in the nation (designated by the CARES Foundation)
NOTABLE PUBLICATIONS
Training the next generation
Journal of Clinical Endocrinology and Metabolism: September 2024 Insulin dynamics and pathophysiology in youth-onset Type 2 diabetes Journal of Clinical Endocrinology and Metabolism: May 2025 Bone accrual trajectories in children and adolescents with perinatal HIV infection Communications Medicine (London): April 2024 Islet antibodies as precision diagnostic tools to characterize heterogeneity in Type 1 diabetes: A systematic review Lead author: Jamie L. Felton, MD Endocrinology and Metabolism Clinics of North America: June 2024 Presentation and care of children with peripheral precocious puberty OUR TEAM ALSO PUBLISHED IN NUMEROUS OTHER PUBLICATIONS, INCLUDING: 65 research publications in 2024
■ Linda A. DiMeglio, MD, MPH , is co-principal investigator of DiabDocs , a National Institutes of Health (NIH)-funded physician-scientist career development program. ■ Riley Children’s and IU School of Medicine have a leading pediatric endocrinology and diabetology fellowship . ■ Alexander R. Tuttle, MD , and Erika L. Zevin, MD , are co- leaders of the IU site for the Endocrine Society Medical Student Engagement Program. ■ IU School of Medicine leadership: Emily C. Walvoord, MD , serves as associate dean for student affairs and Zeina M. Nabhan, MD , is associate dean of graduate medical education.
■ Active in clinical and translational research studies for diabetes and endocrine disorders
BY THE NUMBERS
The diabetes program at Riley Children’s is accredited by the Association of Diabetes Care and Education Specialists.
Clinical locations 8
Patients seen annually Diabetes 1,600 Endocrine 8,230
DIVISION CHIEF Linda A. DiMeglio, MD, MPH Edwin Letzter Professor of Pediatrics, IU School of Medicine > Connect with Dr. DiMeglio on Doximity.
New clinical practice guideline Endocrinologists at Riley Children’s co-authored the Pediatric Endocrine Society Statement on Considerations for Use of Teplizumab in Clinical Practice , published in April 2024.
Years of cumulative experience
Teaching and Learning in Medicine Diabetes Obesity and Metabolism
Physicians 296 Advanced practice providers
17 board certified physicians
See full team member list >
173
Annual Report 2024 – 2025
Refer a patient online
317.944.3889
Made with FlippingBook flipbook maker